Compare CDT & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDT | SCNX |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | United States | United States |
| Employees | 6 | 19 |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 19.0M |
| IPO Year | N/A | N/A |
| Metric | CDT | SCNX |
|---|---|---|
| Price | $1.26 | $0.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 32.9K | ★ 320.3K |
| Earning Date | 04-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,097.38 |
| Revenue Next Year | N/A | $239.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.24 |
| 52 Week High | $11.00 | $2.60 |
| Indicator | CDT | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 35.23 | 48.59 |
| Support Level | $1.24 | $0.37 |
| Resistance Level | $1.66 | $0.47 |
| Average True Range (ATR) | 0.22 | 0.03 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 8.21 | 17.93 |
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The group is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.